Shots: Astellas to receive ~$88.3M as up front for its three products. Daiichi to get rights and obligations, including manufacturing and marketing approvals for Nasea (ramosetron), Perdipine (nicardipine) and Oldeca […]readmore
Tags : Three Therapies